Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Spring;14(2):69-77.

Levetiracetam (levebel) Versus Carbamazepine Monotherapy for Focal Epilepsy in Children: A randomized clinical trial

Javad Akhondian  1 , Farah Ashrafzadeh  1 , Hossein Eslamiyeh  2
Affiliations

Levetiracetam (levebel) Versus Carbamazepine Monotherapy for Focal Epilepsy in Children: A randomized clinical trial

Javad Akhondian et al. Iran J Child Neurol. 2020 Spring.

Abstract

Objective: This study aimed at comparing the effect of a newly approved drug leveitiracetam (LEV) versus carbamazepine (CBZ) in the treatment of childhood focal epilepsy.

Methods & materials: The study population included newly diagnosed children with focal epilepsy (1-16 years old) referring to the Pediatric Neurology Ward of Quaem Hospital, Mashhad, Iran from May 2013 to March 2014. The subjects were randomly treated with LEV or CBZ. Patients were followed for seizure control and drug side effects throughout six months. We assessed liver function and complete blood count for all patients through one month and they were asked about significant side effects, such as drowsiness، restlessness, and skin reaction. Eventually, they were assigned in two groups (n=25) receiving LEV and CBZ.

Results: In our study, two cases in the LEV group were excluded because of severe agitation. Relapsing seizures were observed in 3 (13%) and 10 (40%) patients in LEV and CBZ groups, respectively. The seizure was not repeated in 15 cases (60%) in the CBZ group and 20 cases (87%) in the LEV group. The results of the Chi-squared test showed significant differences in the responses to treatment between the groups (P=0.03). Agitation was the most prevalent complication in the LEV group, whereas drowsiness was more common in the CBZ group. Fortunately, liver enzyme dysfunction and blood cell disturbances were not observed in the subjects.

Conclusion: According to the findings, there were significant differences in controlling seizures between two groups that indicated the effectiveness of LEV (87%) in the suppression of focal seizure.

Keywords: Childhood focal epilepsy; carbamazepine; levetiracetam; pediatric effectiveness.

PubMed Disclaimer

References

    1. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094–1120. - PubMed
    1. Douglas R, Nordli J. Focal and multi focal seizurfes. In: Swaiman KF, editor. Swaiman pediatric neurology. 5 ed. . New York: Elsevier; 2012. pp. 751–7.
    1. Connock M, Frew E, Evans BW, et al. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy A systematic review. Health Technol Assess. 2006;10:ix–118. - PubMed
    1. Ben-Menachem E, Falter U. for the European Levetiracetam Group Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter double-blind, responder selected study evaluating monotherapy. Epilepsia . 2000;41:1276–1283. - PubMed
    1. lawrence D, pellok M, Pellok J. Status epilepticus. In: Swaiman KF, editor. Swaiman pediatric neurology. New York: Elsevier; 2012. pp. 798–808.

LinkOut - more resources